NYSE:NUVBPharmaceuticals
Will TRUST-II Quality-of-Life Data and Global Milestones Change Nuvation Bio's (NUVB) Narrative?
Nuvation Bio recently reported new patient-reported outcomes from the pivotal TRUST-II Phase 2 study of IBTROZI in advanced ROS1-positive non-small cell lung cancer, showing that most patients in North America and Europe experienced improved or stable quality-of-life and symptom scores, including relief from cough and shortness of breath, and also recapped ongoing U.S., European and Asian regulatory milestones for the drug.
A distinctive takeaway is that these outcomes suggest IBTROZI may...